NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$170.8m

Last Updated

2021/05/07 05:02 UTC

Data Sources

Company Financials +

Executive Summary

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. More Details


Snowflake Analysis

Flawless balance sheet and overvalued.

Share Price & News

How has Aptinyx's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: APTX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: APTX's weekly volatility (8%) has been stable over the past year.


Market Performance


7 Day Return

-4.9%

APTX

-4.1%

US Biotechs

-1.7%

US Market


1 Year Return

-38.0%

APTX

25.3%

US Biotechs

51.8%

US Market

Return vs Industry: APTX underperformed the US Biotechs industry which returned 25.3% over the past year.

Return vs Market: APTX underperformed the US Market which returned 51.8% over the past year.


Shareholder returns

APTXIndustryMarket
7 Day-4.9%-4.1%-1.7%
30 Day-12.1%-0.4%1.5%
90 Day-34.6%-10.9%3.1%
1 Year-38.0%-38.0%27.2%25.3%54.4%51.8%
3 Yearn/a28.6%22.0%63.0%52.8%
5 Yearn/a55.3%42.7%127.2%101.9%

Long-Term Price Volatility Vs. Market

How volatile is Aptinyx's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Aptinyx undervalued compared to its fair value and its price relative to the market?

1.11x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate APTX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate APTX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: APTX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: APTX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate APTX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: APTX is good value based on its PB Ratio (1.1x) compared to the US Biotechs industry average (3.4x).


Future Growth

How is Aptinyx forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?

-15.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: APTX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: APTX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: APTX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: APTX is forecast to have no revenue next year.

High Growth Revenue: APTX is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: APTX is forecast to be unprofitable in 3 years.


Past Performance

How has Aptinyx performed over the past 5 years?

-18.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: APTX is currently unprofitable.

Growing Profit Margin: APTX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: APTX is unprofitable, and losses have increased over the past 5 years at a rate of 18.7% per year.

Accelerating Growth: Unable to compare APTX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: APTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.6%).


Return on Equity

High ROE: APTX has a negative Return on Equity (-34.3%), as it is currently unprofitable.


Financial Health

How is Aptinyx's financial position?


Financial Position Analysis

Short Term Liabilities: APTX's short term assets ($149.6M) exceed its short term liabilities ($4.6M).

Long Term Liabilities: APTX's short term assets ($149.6M) exceed its long term liabilities ($114.0K).


Debt to Equity History and Analysis

Debt Level: APTX is debt free.

Reducing Debt: APTX has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: APTX has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: APTX has sufficient cash runway for 2.1 years if free cash flow continues to reduce at historical rates of 14.2% each year.


Dividend

What is Aptinyx current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate APTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate APTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if APTX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if APTX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of APTX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average management tenure


CEO

Norbert Riedel (62 yo)

5.92yrs

Tenure

US$2,117,201

Compensation

Dr. Norbert G. Riedel, Ph.D., serves as Board Member at TRACT Therapeutics, Inc. He serves as Independent Chairman of Eton Pharmaceuticals, Inc., since September 2018 and serves as Industry Advisor at Agen...


CEO Compensation Analysis

Compensation vs Market: Norbert's total compensation ($USD2.12M) is above average for companies of similar size in the US market ($USD993.61K).

Compensation vs Earnings: Norbert's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: APTX's management team is considered experienced (2.3 years average tenure).


Board Members

Experienced Board: APTX's board of directors are considered experienced (3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 47.1%.


Top Shareholders

Company Information

Aptinyx Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Aptinyx Inc.
  • Ticker: APTX
  • Exchange: NasdaqGS
  • Founded: 2015
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$170.773m
  • Shares outstanding: 66.97m
  • Website: https://www.aptinyx.com

Number of Employees


Location

  • Aptinyx Inc.
  • 909 Davis Street
  • Suite 600
  • Evanston
  • Illinois
  • 60201
  • United States

Listings


Biography

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and ne...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/07 05:02
End of Day Share Price2021/05/06 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.